Compare Dell Technologies Inc (DELL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Zoetis Inc — how do they compare? Dell Technologies Inc trades at $586.03 (market cap $365.31B), while Zoetis Inc trades at $74.42 (market cap $30.20B). The key difference: Dell Technologies Inc is far larger — about 12.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Zoetis Inc for 70 Days on average.
| DELL | ZTS | |
|---|---|---|
Market Cap | $365.31B | $30.20B |
Volume | 5,121,365 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $588.67 | $147.53 |
52-Week Low | $111.10 | $69.09 |
Typical Hold Time | 57 Days | 70 Days |
Enterprise Value | $388.20B | $37.76B |
Dividend Yield | 0.44% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $575.33, down 0.63% on the day, but maintains a bullish technical trend with strong support near $566. The stock is buoyed by robust AI server demand, with Q2 2026 EPS beating estimates by 43% and fiscal 2027 revenue guidance raised to approximately $192 billion. Recent news highlights a 20% dividend increase and a $74 billion AI server backlog, fueling investor optimism.
Outlook remains positive given explosive AI-driven growth, but risks include execution on massive orders and competitive pressures. Analysts are largely bullish with a $566.35 consensus target, though the current price slightly exceeds it. Shareholders should monitor margin sustainability and debt levels amid rapid expansion.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
